NYSE:PENPenumbra Stock Price, Forecast & News

$172.42

-0.30 (-0.17 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$167.07

Now: $172.42▼

$174.44

50-Day Range

$159.56

MA: $175.36▼

$191.72

52-Week Range

$121.80

Now: $172.42▼

$194.93

Volume253,908 shs

Average Volume243,823 shs

Market Capitalization$6.05 billion

P/E Ratio158.18

Dividend YieldN/A

Beta0.67

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Penumbra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $191.67, Penumbra has a potential upside of 11.2% from its current price of $172.42.
Amount of Analyst Coverage
Penumbra has only been the subject of 4 research reports in the past 90 days.

3.8 Community Rank

Outperform Votes
Penumbra has received 699 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Penumbra has received 228 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Penumbra has received 75.40% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote “Outperform” if you believe PEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Penumbra does not currently pay a dividend.
Dividend Growth
Penumbra does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,661,795.00 in company stock.
Percentage Held by Insiders
Only 9.60% of the stock of Penumbra is held by insiders.
Percentage Held by Institutions
83.77% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Penumbra are expected to grow in the coming year, from ($0.02) to $1.25 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Penumbra is 158.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.11.
Price to Earnings Ratio vs. Sector
The P/E ratio of Penumbra is 158.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.17.
Price to Book Value per Share Ratio
Penumbra has a P/B Ratio of 12.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.59 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:PEN

Previous Symbol

CUSIPN/A

CIK1321732

Webwww.penumbrainc.com

Phone510-748-3200

Debt

Debt-to-Equity Ratio0.15

Current Ratio5.15

Quick Ratio3.27

Price-To-Earnings

Trailing P/E Ratio158.18

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$547.41 million

Price / Sales11.05

Cash Flow$1.25 per share

Price / Cash Flow138.02

Book Value$13.92 per share

Price / Book12.39

Profitability

EPS (Most Recent Fiscal Year)$0.98

Net Income$48.46 million

Net Margins7.04%

Return on Equity5.72%

Return on Assets4.28%

Miscellaneous

Employees2,700

Outstanding Shares35,070,000

Market Cap$6.05 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

Penumbra (NYSE:PEN) Frequently Asked Questions

How has Penumbra's stock been impacted by COVID-19 (Coronavirus)?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PEN stock has decreased by 2.5% and is now trading at $172.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Penumbra?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Penumbra.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Penumbra.

How were Penumbra's earnings last quarter?

Penumbra Inc (NYSE:PEN) announced its quarterly earnings data on Thursday, May, 7th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.10 by $0.06. The company had revenue of $137.33 million for the quarter, compared to the consensus estimate of $136.28 million. Penumbra had a net margin of 7.04% and a return on equity of 5.72%. The company's revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.23 EPS. View Penumbra's earnings history.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its first quarter 2020 After-Hours earnings guidance on Monday, April, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $137-137.3 million, compared to the consensus revenue estimate of $140.9 million.

What price target have analysts set for PEN?

6 analysts have issued 1-year price objectives for Penumbra's stock. Their forecasts range from $180.00 to $214.00. On average, they anticipate Penumbra's stock price to reach $191.67 in the next year. This suggests a possible upside of 11.2% from the stock's current price. View analysts' price targets for Penumbra.

Has Penumbra been receiving favorable news coverage?

Press coverage about PEN stock has been trending very negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Penumbra earned a news impact score of -3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutPenumbra.

Who are some of Penumbra's key competitors?

Some companies that are related to Penumbra include ResMed (RMD), Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Novocure (NVCR), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA) and Merit Medical Systems (MMSI). View all competitors.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), AbbVie (ABBV), DexCom (DXCM), Intuitive Surgical (ISRG), Medtronic (MDT), Boeing (BA), salesforce.com (CRM) and Gilead Sciences (GILD).

Who are Penumbra's key executives?

Penumbra's management team includes the following people:

Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.85%), William Blair Investment Management LLC (3.61%), Wellington Management Group LLP (3.18%), Clearbridge Investments LLC (2.91%), Baillie Gifford & Co. (2.73%) and State Street Corp (2.28%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View institutional ownership trends for Penumbra.

Which major investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Deutsche Bank AG, Alliancebernstein L.P., Clearbridge Investments LLC, Principal Financial Group Inc., Squarepoint Ops LLC, and Trexquant Investment LP. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, and Thomas Wilder. View insider buying and selling activity for Penumbra.

Which major investors are buying Penumbra stock?

PEN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Wellington Management Group LLP, Invesco Ltd., Balyasny Asset Management LLC, Champlain Investment Partners LLC, William Blair Investment Management LLC, Trillium Asset Management LLC, and Columbus Circle Investors. View insider buying and selling activity for Penumbra.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $172.42.

How big of a company is Penumbra?

Penumbra has a market capitalization of $6.05 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff